Like Ozempic and Wegovy, its a glucagon-like peptide-1 (GLP-1) agonist medication
In clinical trials, the triple agonist (GLP-1 + GIP + glucagon) produced the highest weight loss ever recorded in a drug trial
Sleep and recovery: Deeper, more restorative sleep becomes a reliable pattern rather than an occasional effect Post-exercise recovery improves less soreness, faster return to baseline Minor soft tissue aches (old nagging injuries) may begin to feel better Body composition (early signals): Skin quality begins to improve increased hydration and elasticity from GH-driven collagen synthesis Subtle reduction in subcutaneous water retention, particularly around the midsection Appetite patterns shift some users report increased hunger (GH is a counterregulatory hormone), others report better appetite regulation Energy and mood: More consistent energy levels through the day Improved sense of well-being GH influences neurotransmitter function and this often manifests as a subtle mood elevation DAC vs no-DAC difference: By week 2-4, DAC users on a 1-2x/week schedule have accumulated sustained IGF-1 elevation
Anesthesiologist has a great sense of humor
A randomized clinical trial published in May 2026 in The Lancet investigated whether semaglutide, a GLP-1 peptide that acts as a GLP-1 receptor agonist and is approved for obesity treatment, was associated with changes in alcohol consumption among adults living with both obesity and alcohol use disorder
However, like many medications, Ozempic comes with its own set of side effects
